List of Ermeza drug patents

Ermeza is owned by Mylan.

Ermeza contains Levothyroxine Sodium.

Ermeza has a total of 1 drug patent out of which 0 drug patents have expired.

Ermeza was authorised for market use on 29 April, 2022.

Ermeza is available in solution;oral dosage forms.

The generics of Ermeza are possible to be released after 27 February, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9345772 MYLAN Liquid levothyroxine formulations
Feb, 2035

(11 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 29 April, 2022

Treatment: NA


More Information on Dosage

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic